SURVEY How do you feel about Elon Musk's alliance with Donald Trump? Take our poll. NasdaqGS - Nasdaq Real Time Price ? USD BeiGene, Ltd. (BGNE) Follow Compare 220.63 +0.71 (+0.32%) At close: 4:00 PM EDT 220.63 0.00 (0.00%) After hours: 4:35 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Top Midday Gainers Top Midday Gainers PREMIUM MT Newswires ? 4 hours ago MLI BGNE +0.32% BeiGene Receives Positive CHMP Opinions for TEVIMBRA? as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma SAN MATEO, Calif., October 21, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued positive opinions recommending an extended authorization for TEVIMBRA? (tislelizumab) in gastric or gastroesophageal junction (G/GEJ) adenocarcinoma and esophageal squamous cell carcinoma (ESCC). Business Wire ? yesterday BEIGF BGNE +0.32% Recent 7.2% pullback isn't enough to hurt long-term BeiGene (NASDAQ:BGNE) shareholders, they're still up 60% over 5 years If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see... Simply Wall St. ? 5 days ago BEIGF BGNE +0.32% BeiGene Highlights Waldenstr?m’s Macroglobulinemia Innovation at IWWM 2024 SAN MATEO, Calif., October 16, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating BRUKINSA? (zanubrutinib), Bruton tyrosine kinase (BTK) chimeric degradation activation compound (CDAC) degrader BGB-16673 and B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax in patients with Waldenstr?m’s macroglobulinemia at the 12th International Workshop on Waldenstr?m's Macroglobulinemia (IWWM) Oct. 17-19 in Prag Business Wire ? 6 days ago BEIGF BGNE +0.32% Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3 Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The third quarter saw a significant rally in global equities markets, driven by robust stock performance from the U.S., international developed, […] Insider Monkey ? 12 days ago BGNE +0.32% BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? BeiGene (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Zacks ? 15 days ago BGNE +0.32% FHTX 3 Stocks That May Be Trading Below Intrinsic Value By Up To 48.2% With global markets reaching new highs following the Federal Reserve's recent rate cut, investors are eagerly seeking opportunities that may be trading below their intrinsic value. In this favorable market environment, identifying undervalued stocks can be particularly rewarding, as these investments have the potential to offer significant upside when their true worth is recognized. Simply Wall St. ? 25 days ago MALRF MALRY BEIGF BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA?, for Treatment of ESCC and Gastric/GEJ Cancers SAN MATEO, Calif., September 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recognizes the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA? (tislelizumab-jsgr), for the first-line treatment of patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1 (>1%) and gastric/gastroes Business Wire ? 25 days ago BEIGF BGNE +0.32% Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors SAN MATEO, Calif., September 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board’s Audit Committee, effective September 27, 2024. Business Wire ? 26 days ago BEIGF BGNE +0.32% FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients On Thursday, 26 September, the FDA's Oncologic Drugs Advisory Committee will discuss the use of immune checkpoint inhibitors in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma. The FDA notes that the current labeling for approved checkpoint inhibitors in this indication reflects broad approvals in the intent to treat patient populations agnostic of programmed death cell ligand-1 (PD-L1) expression. Also Read: Ca Benzinga ? 27 days ago CELG-RT MRK BGNE +0.32% High Growth Tech Stocks To Watch In September 2024 The market has climbed 2.6% in the last 7 days and is up 31% over the last 12 months, with earnings forecast to grow by 15% annually. In this thriving environment, identifying high-growth tech stocks that align with these robust conditions can be crucial for investors looking to capitalize on future opportunities. Simply Wall St. ? last month LITE BEIGF BGNE +0.32% BeiGene’s TEVIMBRA gains approval for OSCC in Israel Further filings in the region for first-line oesophageal squamous cell carcinoma and gastric cancer are anticipated. Pharmaceutical Technology ? last month BGNE +0.32% BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA? for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy HERZLIYA, Israel, September 17, 2024--Tevimbra has been approved in Israel Business Wire ? last month BEIGF BGNE +0.32% BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is proud to join the global community in raising awareness about lymphoma on World Lymphoma Awareness Day (WLAD). Lymphoma, a type of blood cancer affecting millions of people worldwide, is the focus of WLAD, which serves as a key platform during Blood Cancer Awareness Month to educate the public on the emotional and physical challenges faced by those living with the disease. PR Newswire ? last month BEIGF BGNE +0.32% SK hynix And 2 More Stocks Estimated To Be Trading Below Fair Value As global markets grapple with concerns over economic slowdowns and fluctuating indices, investors are increasingly seeking opportunities in undervalued stocks. In such volatile times, identifying companies trading below their fair value can offer a strategic advantage for long-term growth. Simply Wall St. ? last month BEIGF BGNE +0.32% BeiGene Announces Updates to Commercial Leadership Team SAN MATEO, Calif., September 09, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. Business Wire ? last month BEIGF BGNE +0.32% BeiGene Highlights TEVIMBRA? Data in Lung and Gastrointestinal Cancers at ESMO 2024 BASEL, Switzerland, September 09, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data for TEVIMBRA? (tislelizumab) at the European Society of Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, September 13-17, 2024. BeiGene has seven abstracts accepted at ESMO 2024, with one selected for the special session revisiting the ESMO Virtual Plenary held in February 2024. Business Wire ? last month BEIGF BGNE +0.32% Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High? The consensus price target hints at a 27.8% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Zacks ? last month BGNE +0.32% 3 US Stocks That Could Be Trading At A Discount As the major U.S. stock indexes edged higher recently, investors are keeping a close eye on significant earnings reports and economic indicators that could influence market sentiment. Amid this cautious optimism, identifying undervalued stocks can be crucial for those looking to capitalize on potential discounts in the current market landscape. Simply Wall St. ? last month MAR BEIGF BGNE +0.32% BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference SAN MATEO, Calif., August 28, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, with a fireside chat at 10 a.m. EDT. Business Wire ? last month BEIGF BGNE +0.32% Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is HANG SENG INDEX Return BGNE HANG SENG INDEX YTD +22.33% +20.25% 1-Year +33.55% +19.37% 3-Year -41.21% -21.21%
